Physician profile
Matthew Edwards
NPI 1588979470
$3,783.47
in general payments reported to CMS, 2019-2025
32 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.10 · 2020: $16.20 · 2021: $14.80 · 2022: $76.96 · 2023: $805 · 2024: $1,556 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,594.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $699.44 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $491.97 | 2023-2025 | Freestyle Libre 3 |
| Abbvie INC. | $403.07 | 2022-2025 | Vraylar, Qulipta |
| Pfizer INC. | $385.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $267.16 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $260.40 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $183.30 | 2024-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $141.32 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Davol INC. | $138.70 | 2025 | Arista |
| Merck Sharp & Dohme LLC | $84.15 | 2022-2025 | Zerbaxa, Recarbrio, Keytruda |
| Amgen INC. | $75.35 | 2023-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $73.86 | 2024 | Veozah |
| Exact Sciences Corporation | $62.38 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $61.18 | 2019-2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $47.29 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $42.96 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $41.16 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.46 | 2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $30.44 | 2023-2025 | |
| Daiichi Sankyo INC. | $25.97 | 2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $25.85 | 2024 | Voquezna |
| Ambu INC. | $23.48 | 2023 | |
| Acera Surgical, INC. | $23.14 | 2025 | Restrata Wound Matrix |
| Takeda Pharmaceuticals U.S.A., INC. | $21.29 | 2024 | Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $20.50 | 2024 | Libtayo |
| Philips North America LLC | $18.76 | 2024 | (Ck7) Extended Holter |
| Lemaitre Vascular, INC. | $17.96 | 2022 | |
| Dexcom, INC. | $17.80 | 2023 | Dexcom G6 Transmitter |
| Adaptive Biotechnologies Corporation | $15.47 | 2024 | Clonoseq |
| Morphosys, US INC. | $15.23 | 2023 | Monjuvi |
| Ethicon US, LLC | $14.80 | 2021 | |
| Intra-Sana Laboratories | $14.31 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.